# An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

> **NCT02271347** · PHASE2 · WITHDRAWN · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Ebola Virus

## Interventions

- **DRUG:** CMX001

## Key facts

- **NCT ID:** NCT02271347
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Suspended Development Program
- **Last updated:** 2015-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02271347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02271347, "An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02271347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*